Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678893 | 0.82 | GPBAR1 (0.39) | KMT2AALDH1A1MEN1GPBAR1PKM | |
| SCHEMBL6718159 | 0.82 | GPBAR1 (0.39) | KMT2AALDH1A1MEN1GPBAR1PKM | |
| SCHEMBL6716879 | 0.70 | CNR2 (0.43) | KMT2AALDH1A1LMNA | |
| SCHEMBL7005686 | 0.64 | ALDH1A1 (0.44) | KMT2AALDH1A1MEN1 | |
| SCHEMBL8133573 | 0.61 | CASP3 (0.57) | KMT2AALDH1A1MEN1LMNAL3MBTL1 | |
| SCHEMBL1964302 | 0.61 | KMT2A (0.49) | KMT2AALDH1A1MEN1L3MBTL1 | |
| SCHEMBL17251633 | 0.61 | TDP1 (0.49) | KMT2AALDH1A1GPBAR1LMNAMMP1 | |
| SCHEMBL663552 | 0.61 | KMT2A (0.76) | KMT2AALDH1A1MEN1LMNAMMP1 | |
| SCHEMBL16457648 | 0.60 | RXFP1 (0.78) | KMT2AALDH1A1MEN1PKMLMNA | |
| SCHEMBL10113207 | 0.60 | TSHR (0.78) | KMT2AALDH1A1MEN1PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2004014354-A1 | 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP11 | KMT2A 3890/4885ALDH1A1 430/4885MEN1 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.